A ticker rips 80% before lunch on a press release, then bleeds for three weeks while volume stays strangely heavy. Sometimes that is just a normal fade. Sometimes it is toxic financing: a lender converting debt into discounted shares and selling them into every bid. This post explains how the structure works, walks through a clearly hypothetical conversion spiral number by number, and shows you where the terms hide in filings before you size a trade.
In this article
- What is toxic financing?
- How does a VWAP-discount convertible note work?
- A worked example: the conversion spiral in numbers (hypothetical)
- Toxic financing vs other ways small caps raise money
- How do you spot toxic financing in filings?
- How should a trader think about a stock with toxic debt?
- FAQ
- What are the alternatives to toxic convertible financing?
- How do reverse splits fit into toxic financing?
- How do you find out who the lender is?
- Tools to track toxic financing and dilution
- Toxic financing in Canadian small caps (TSXV/CSE)
- More questions traders ask
What is toxic financing?
Toxic financing is a convertible note or convertible preferred deal where the conversion price floats at a discount to the recent market price, so the lower the stock goes, the more shares the lender receives.
That is the whole problem in one sentence. A normal convertible has a fixed conversion price, so the holder only wins if the stock goes up. A floating, discounted conversion price flips the incentive. The holder gets paid in shares no matter where the stock trades, and every drop increases the share count they can claim. Traders also call these deals death spiral financing, and for good reason.
Companies that sign these deals are usually small, cash-burning and short on alternatives. If a cleaner offering were available on decent terms, most boards would take it. So the existence of a toxic note is itself information about the balance sheet. If you are new to how share counts expand, start with how to tell if a stock is diluting.
How does a VWAP-discount convertible note work?
The lender hands the company cash and gets a note that can be converted into common stock using a formula instead of a fixed price. The specific terms vary deal to deal, but these are the pieces you will keep running into:
- Variable conversion price: something like 70% to 80% of the lowest trading price or lowest VWAP over a lookback window.
- Lookback window: the number of trading days the formula scans, often the prior 10 to 20 days. Using the lowest price in the window, not the average, makes the discount even steeper in a falling tape.
- Original issue discount (OID): the company may receive less cash than the face value it owes.
- Beneficial ownership blocker: commonly 4.99% or 9.99%. The holder cannot own more than that at once, so they convert, sell, and convert again. The blocker caps how much they hold, not how much they can convert over time.
- Share reserve: the company sets aside authorized shares, often a multiple of what the note would currently convert into.
- Default penalties: missed payments or falling below listing standards can raise the principal or deepen the discount.
A worked example: the conversion spiral in numbers (hypothetical)
Everything in this section is hypothetical. The company, the terms and the price path are made up to show the mechanics. Real deals have different terms, and real prices do not move in neat steps.
Setup: a small cap with 20,000,000 shares outstanding trades at $1.00. It signs a $1,000,000 convertible note. Conversion price is 70% of the lowest daily VWAP over the prior 10 trading days. Blocker is 4.99%, roughly 1,000,000 shares. The holder converts $200,000 at a time, sells the shares into the market, and repeats. We assume each round of selling pushes the lowest VWAP lower.
| Round | Lowest 10-day VWAP | Conversion price (70%) | Principal converted | New shares | Cumulative new shares | % of original 20M |
|---|---|---|---|---|---|---|
| 1 | $1.00 | $0.700 | $200,000 | 285,714 | 285,714 | 1.43% |
| 2 | $0.80 | $0.560 | $200,000 | 357,143 | 642,857 | 3.21% |
| 3 | $0.60 | $0.420 | $200,000 | 476,190 | 1,119,047 | 5.60% |
| 4 | $0.45 | $0.315 | $200,000 | 634,921 | 1,753,968 | 8.77% |
| 5 | $0.33 | $0.231 | $200,000 | 865,801 | 2,619,769 | 13.10% |
Read the table slowly. The holder converts the exact same $200,000 every round, but round five delivers about three times as many shares as round one. The company raised $1,000,000 once. The share count grew 13.1%, and in this hypothetical path the stock fell 67% along the way.
Now look at it from the holder’s side. Every conversion is priced 30% below the lowest recent VWAP. As long as they can sell anywhere near the market, the spread is close to locked in whether the stock rallies or dumps. That is why the selling pressure does not stop on bad days. Bad days make the next conversion cheaper.
What if the price falls harder?
Same hypothetical, but say the lowest VWAP had dropped to $0.10 by the final round. Conversion price becomes $0.07, and that last $200,000 alone turns into 2,857,143 shares, more than the first five rounds above combined. This is the spiral: lower price, more shares, more selling, lower price. It usually ends with the note fully converted, a request for more authorized shares, a reverse stock split, or a new note to fund the next quarter.
Toxic financing vs other ways small caps raise money
Not every raise is toxic. The key questions are how the price is set and who controls the timing.
| Structure | How the share price is set | Who controls timing | Main risk to existing holders |
|---|---|---|---|
| Priced offering | Fixed, announced up front | Company and underwriter, one event | Immediate dilution, known size |
| ATM program | Market price at time of sale | Company, over time | Steady supply into strength |
| Fixed-price convertible | Fixed conversion price | Holder, but only worth it above that price | Overhang near the conversion price |
| Variable-price (toxic) convertible | Discount to recent low or VWAP | Holder, repeatedly | Share count grows as price falls |
For the at-the-market side of this, see what an ATM offering does to a small cap.
How do you spot toxic financing in filings?
Go to the documents, not the press release. The press release will say “strategic financing.” The exhibit will say “lowest trading price.” Use this checklist:
- 8-K items: Item 1.01 (material agreement), Item 2.03 (direct financial obligation) and Item 3.02 (unregistered sale of equity). The item list is on the SEC’s Form 8-K; our 8-K items guide explains what each means for small caps.
- Search the exhibits for phrases like “variable conversion price,” “lowest trading price,” “VWAP,” “original issue discount” and “4.99%.” EDGAR full-text search lets you search filings for exact phrases.
- Resale registrations: an S-1 or S-3 listing a note holder as a selling stockholder means conversion shares can hit the market freely.
- 10-Q and 10-K notes: look for convertible notes payable, derivative liabilities and a list of conversions after quarter end.
- Proxy statements: a vote to increase authorized shares or approve a reverse split, shortly after a note, is a pattern worth noticing.
For Canadian listings, filings live on SEDAR+, and TSXV and CSE issuers operate under their own exchange pricing policies. Read the actual financing news release and material change report instead of assuming US-style terms apply.
How should a trader think about a stock with toxic debt?
Treat it as known supply sitting overhead. That is not a prediction about any ticker, it is just how the incentives line up. Rallies give the holder better prices to sell conversion shares into. Volume spikes give them liquidity. A run that looks like momentum can be absorbed by someone who bought at a 30% discount and does not care about your chart.
Practical habits: check whether a note exists before you take a position, estimate how many shares the remaining principal could become at today’s price, and size smaller when the answer is ugly. The Fockets Terminal helps with the grunt work. It ties big moves to the filing behind them, translates filings into plain English and shows how many more shares a company may issue. You still have to decide what that means for your own risk.
FAQ
Is toxic financing illegal?
Generally no. These are negotiated contracts disclosed in filings. The SEC has brought cases alleging that certain convertible note buyers operated as unregistered dealers, but the structure itself is not banned.
Why would a company accept a toxic convertible note?
Usually because it needs cash quickly and cannot get better terms from an underwritten offering or a bank. It is often a funding source of last resort.
How do I know if a stock has toxic debt?
Read the 8-K exhibits and the debt footnotes in the latest 10-Q or 10-K. Variable conversion language tied to a lowest price or VWAP is the tell.
Can a stock recover after toxic financing?
It can, if the note is paid off or fully converted and the business improves. But the dilution already done does not reverse, and many companies sign another note when the first runs out.
What are the alternatives to toxic convertible financing?
The main alternatives are underwritten or priced offerings, registered direct offerings, ATM programs, fixed-price convertibles, warrant exercises and bank or asset-based loans. Each one sets the price or the terms in a way that does not automatically hand more shares to the investor as the stock falls. The catch is access. A cash-burning microcap with a small float, thin volume and no revenue to lend against often cannot find an underwriter, cannot raise enough through an ATM, and has no collateral a bank will accept.
- Priced or registered direct offerings: fixed price, one event. See registered direct vs public offering.
- ATM programs: need a shelf and enough daily volume to sell into. See shelf offering vs ATM.
- Warrant exercises: only work if the stock trades above the exercise price, or if the company offers an inducement.
- Bank or asset-based loans: need assets or cash flow to secure them.
How do reverse splits fit into toxic financing?
A reverse split raises the per-share price and frees up authorized shares, but it does not undo the dilution or stop the note from converting. Companies often use one to get back above an exchange minimum bid, which we cover in Nasdaq minimum bid price deficiency. Because the authorized share count usually stays put while outstanding shares shrink, the company suddenly has more room to issue conversion shares. If the note is still outstanding, the formula keeps pricing off the new, post-split trading price, so discounted conversions can start right back up. The pattern is laid out in reverse split then offering.
How do you find out who the lender is?
The lender is named in the filing itself, usually in the note or securities purchase agreement attached as an exhibit to the 8-K. The first page of the agreement lists the parties. If conversion shares are later registered for resale, the S-1 or S-3 includes a selling stockholder table showing the holder’s name and how many shares they can sell. Our S-1 resale registration guide shows where that table sits. Once you have the name, you can search EDGAR for other filings mentioning the same holder and form your own view.
Tools to track toxic financing and dilution
- EDGAR full-text search: search exhibits for phrases like “lowest trading price” or a lender’s name.
- The company’s EDGAR filing index: scan the 8-Ks, S-1s and 10-Qs in date order to see notes, resale registrations and conversions.
- SEDAR+: for Canadian issuers. Walkthrough in how to check dilution on SEDAR+.
- Fockets Terminal: ties a move to the filing behind it, summarizes filings in plain English and shows how many more shares a company is allowed to issue.
Toxic financing in Canadian small caps (TSXV/CSE)
In Canada the equivalent deals usually show up as convertible debentures, and the terms are in the financing news release and the material change report on SEDAR+. Look for the conversion price, whether it is fixed or tied to market price, any adjustment clauses, attached warrants and the hold period. The TSXV and CSE each have their own pricing policies that limit how deals can be priced, so check the exchange’s current policy rather than assuming US rules. Related reading: TSXV private placements and shares for debt on the TSXV.
More questions traders ask
Is toxic debt the same as toxic financing?
Close, but not quite. Traders say toxic financing for the deal structure and toxic debt for the variable-price notes still outstanding on the balance sheet. In banking, toxic debt or toxic assets usually means loans unlikely to be repaid, which is a different idea. And financial toxicity is a healthcare term for the cost burden of treatment on patients, unrelated to convertible notes.
Is toxic financing ever a good deal for the company?
It is a trade-off, not a free lunch. The upside is fast cash with no underwriter and little paperwork. The downside is that dilution grows as the price falls, the holder controls conversion timing, and default penalties can raise what is owed. This is education, not advice to any company.
Does a toxic note always send a stock to zero?
No. As covered above, a stock can recover once the note is paid off or fully converted and the business improves. The note is overhead supply to account for, not a guaranteed outcome.
Want to see how other traders read these filings in real time? Join the free Fockets stock trading Discord, ask questions, and learn to do the work yourself instead of following anyone blindly.
Keep reading
Disclaimer: This post is for educational purposes only and is not financial advice. Fockets Trading does not provide buy or sell recommendations or price targets. All examples labelled hypothetical are illustrations, not real securities. Trading small caps involves substantial risk, including the loss of your entire investment. Do your own research and size your own risk.
